356 related articles for article (PubMed ID: 12134948)
21. Phenylpropionic acid-based cyclic prodrugs of opioid peptides that exhibit metabolic stability to peptidases and excellent cellular permeation.
Gudmundsson OS; Nimkar K; Gangwar S; Siahaan T; Borchardt RT
Pharm Res; 1999 Jan; 16(1):16-23. PubMed ID: 9950273
[TBL] [Abstract][Full Text] [Related]
22. Effects of amino acid chirality and the chemical linker on the cell permeation characteristics of cyclic prodrugs of opioid peptides.
Liederer BM; Fuchs T; Vander Velde D; Siahaan TJ; Borchardt RT
J Med Chem; 2006 Feb; 49(4):1261-70. PubMed ID: 16480263
[TBL] [Abstract][Full Text] [Related]
23. Characterization of P-glycoprotein mediated transport of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor, across MDR1-MDCK and Caco-2 cell monolayers.
Zhang Y; Benet LZ
Pharm Res; 1998 Oct; 15(10):1520-4. PubMed ID: 9794492
[TBL] [Abstract][Full Text] [Related]
24. Factors that restrict intestinal cell permeation of cyclic prodrugs of an opioid peptide (DADLE): Part II. Role of metabolic enzymes in the intestinal mucosa.
Ouyang H; Chen W; Andersen TE; Steffansen B; Borchardt RT
J Pharm Sci; 2009 Jan; 98(1):349-61. PubMed ID: 18537150
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and conformational analysis of a coumarinic acid-based cyclic prodrug of an opioid peptide with modified sensitivity to esterase-catalyzed bioconversion.
Ouyang H; Vander Velde DG; Borchardt RT; Siahaan TJ
J Pept Res; 2002 Apr; 59(4):183-95. PubMed ID: 11972752
[TBL] [Abstract][Full Text] [Related]
26. Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2.
Mease K; Sane R; Podila L; Taub ME
J Pharm Sci; 2012 May; 101(5):1888-97. PubMed ID: 22359351
[TBL] [Abstract][Full Text] [Related]
27. Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT).
Guo A; Marinaro W; Hu P; Sinko PJ
Drug Metab Dispos; 2002 Apr; 30(4):457-63. PubMed ID: 11901101
[TBL] [Abstract][Full Text] [Related]
28. The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport.
Dahan A; Sabit H; Amidon GL
AAPS J; 2009 Jun; 11(2):205-13. PubMed ID: 19319690
[TBL] [Abstract][Full Text] [Related]
29. Transport characteristics of peptidomimetics. Effect of the pyrrolinone bioisostere on transport across Caco-2 cell monolayers.
Sudoh M; Pauletti GM; Yao W; Moser W; Yokoyama A; Pasternak A; Sprengeler PA; Smith AB; Hirschmann R; Borchardt RT
Pharm Res; 1998 May; 15(5):719-25. PubMed ID: 9619780
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of P-glycoprotein-mediated renal drug interactions in an MDR1-MDCK model.
Karyekar CS; Eddington ND; Garimella TS; Gubbins PO; Dowling TC
Pharmacotherapy; 2003 Apr; 23(4):436-42. PubMed ID: 12680473
[TBL] [Abstract][Full Text] [Related]
31. Dipeptide prodrug approach to evade efflux pumps and CYP3A4 metabolism of lopinavir.
Patel M; Sheng Y; Mandava NK; Pal D; Mitra AK
Int J Pharm; 2014 Dec; 476(1-2):99-107. PubMed ID: 25261710
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and evaluation of the physicochemical properties of esterase-sensitive cyclic prodrugs of opioid peptides using coumarinic acid and phenylpropionic acid linkers.
Wang B; Nimkar K; Wang W; Zhang H; Shan D; Gudmundsson O; Gangwar S; Siahaan T; Borchardt RT
J Pept Res; 1999 Apr; 53(4):370-82. PubMed ID: 10406215
[TBL] [Abstract][Full Text] [Related]
33. Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1.
Luo FR; Paranjpe PV; Guo A; Rubin E; Sinko P
Drug Metab Dispos; 2002 Jul; 30(7):763-70. PubMed ID: 12065434
[TBL] [Abstract][Full Text] [Related]
34. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.
Profit L; Eagling VA; Back DJ
AIDS; 1999 Sep; 13(13):1623-7. PubMed ID: 10509562
[TBL] [Abstract][Full Text] [Related]
35. Optimizing oral absorption of peptides using prodrug strategies.
Borchardt RT
J Control Release; 1999 Nov; 62(1-2):231-8. PubMed ID: 10518655
[TBL] [Abstract][Full Text] [Related]
36. Cyclosporin A affects the bioavailability of ginkgolic acids via inhibition of P-gp and BCRP.
Li L; Yao QQ; Xu SY; Hu HH; Shen Q; Tian Y; Pan LY; Zhou H; Jiang HD; Lu C; Yu LS; Zeng S
Eur J Pharm Biopharm; 2014 Nov; 88(3):759-67. PubMed ID: 24980806
[TBL] [Abstract][Full Text] [Related]
37. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
Dahan A; Amidon GL
Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926
[TBL] [Abstract][Full Text] [Related]
38. Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells.
Balimane PV; Chong S; Patel K; Quan Y; Timoszyk J; Han YH; Wang B; Vig B; Faria TN
Arch Pharm Res; 2007 Apr; 30(4):507-18. PubMed ID: 17489369
[TBL] [Abstract][Full Text] [Related]
39. [Absorption and transport of isoflavonoid compounds from Tongmai formula across human intestinal epithelial (Caco-2) cells in vitro].
Wang FR; Yang XW
Zhongguo Zhong Yao Za Zhi; 2017 Aug; 42(16):3206-3212. PubMed ID: 29171242
[TBL] [Abstract][Full Text] [Related]
40. Evidence for a polarized efflux system in CACO-2 cells capable of modulating cyclosporin A transport.
Augustijns PF; Bradshaw TP; Gan LS; Hendren RW; Thakker DR
Biochem Biophys Res Commun; 1993 Dec; 197(2):360-5. PubMed ID: 7903526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
